18TH WORLD CONGRESS INSULIN RESISTANCE DIABETES &
CARDIOVASCULAR DISEASE
| SESSION 1: LIPOTOXICITY: THE PATHOPHYSIOLOGIC LINK BEHIND THE CARDIO-METABOLIC SYNDROME | 8:10:00 | 9:50:00 | JOIN |
| SESSION 2: HEART DISEASE IN WOMEN | 9:50:00 | 11:10:00 | JOIN |
| An Approach to Managing Lipids: Oral Nonstatin Therapies for Lowering LDL-C: Supported by ESPERION Therapeutics | 11:10:00 | 11:55:00 | JOIN |
| SESSION 3: LANCET DIABETES & ENDOCRINOLOGY & 18 WCIRDC JOINT SESSION: COVID-19 DM & METABOLISM | 11:55:00 | 13:15:00 | JOIN |
| SESSION 4: CME Symposium: Heart Failure and Kidney Disease: The Next Epidemics Supported by AstraZeneca | 13:15:00 | 15:10:00 | JOIN |
| SESSION 5: THE EFFECTS OF CANCER AND CANCER THERAPY ON METABOLIC DISORDERS | 15:10:00 | 16:30:00 | JOIN |
| SESSION 5A: INSULIN RESISTANCE & T2D | 16:30:00 | 17:00:00 | JOIN |
| Day 1 Summary Session | 17:00:00 | 18:00:00 | JOIN |
| SESSION 6: PEDIATRIC OBESITY MANAGEMENT | 8:00:00 | 9:15:00 | JOIN |
| SESSION 7: WHAT SHOULD WE TARGET TO TREAT INSULIN RESISTANCE? – POINT-COUNTER-POINT | 9:15:00 | 10:15:00 | JOIN |
| SESSION 8: LIPIDS | 10:15:00 | 11:35:00 | JOIN |
| Potential Mechanisms Responsible for the Effect of Incretins on Atherosclerosis Supported By: Lilly | 11:35:00 | 12:20:00 | JOIN |
| SESSION 9: INSULIN FOCUSED MANAGEMENT OF DM - TODAY AND TOMORROW | 12:20:00 | 14:00:00 | JOIN |
| SESSION 10: METABOLISM & 18 WCIRDC JOINT SESSION: HISTORY OF INSULIN RESISTANCE & METABOLISM | 14:00:00 | 15:40:00 | JOIN |
| SESSION 11: ADVANCED TECHNOLOGIES & GENETICS FOR UNDERSTANDING & MANAGING IR & T2D | 15:40:00 | 17:00:00 | JOIN |
| Day 2 Summary Session | 17:00:00 | 18:00:00 | JOIN |
| SESSION 12: NAFLD/NASH | 8:00:00 | 8:55:00 | JOIN |
| SESSION 13: ATHEROSCLEROSIS CARDIOVASCULAR DISEASE | 8:55:00 | 10:15:00 | JOIN |
| Jardiance (empagliflozin) tablets: A Review of Multiple Clinical Trials and Approved Indications | 10:15:00 | 11:00:00 | JOIN |
| SESSION 14: OBESITY - INTERVENTIONS | 11:00:00 | 12:40:00 | JOIN |
| SESSION 15: COVID-19 PATHOPHYSIOLOGY AND ADVANCED MANAGEMENT | 13:25:00 | 15:05:00 | JOIN |
| SESSION 16: CME Symposium: Emerging Standard of Care in the Prevention of Cardiovascular Morbidity and Mortality | 15:05:00 | 16:35:00 | JOIN |
| Day 3 Summary Session | 16:35:00 | 17:35:00 | JOIN |
| SESSION 17: CARDIOVASCULAR DISEASE AND INSULIN RESISTANCE | 8:00:00 | 9:40:00 | JOIN |
| SESSION 18: CONTEMPORARY ASPECTS OF DIABETES MANAGEMENT | 9:40:00 | 11:00:00 | JOIN |
| SESSION 19: OBESITY AND CVD IN TYPE 1 DIABETES | 11:30:00 | 12:50:00 | JOIN |
| SESSION 20: THE KIDNEY IN DIABETES | 12:50:00 | 13:45:00 | JOIN |
| SESSION 21: ABSTRACT – ORAL PRESENTATION | 13:45:00 | 14:30:00 | JOIN |
| VASCEPA (icosapent ethyl): Elevating the Standard of Care Supported By: Amarin | 13:45:00 | 14:30:00 | JOIN |
| SESSION 22: HEART FAILURE AND MANAGEMENT | 14:30:00 | 15:45:00 | JOIN |
| Day 4 Summary Session | 15:45:00 | 17:05:00 | JOIN |